Torrent Pharma Shares Hit 52-Week High After In-Line Q4 Results

$TORNTPHARM rmaceuticals shares surged to a 52-week high on Monday following its Q4 earnings announcement. Despite a 27% year-on-year decline in quarterly net profit due to one-time costs related to the J.B. Pharma acquisition, the company delivered a strong operational performance that boosted investor sentiment. India business revenue jumped 43% to ₹2,215 crore, driven by 15% volume growth and a successful semaglutide launch that grew 38%. Brazil revenue rose 30% to ₹455 crore, while the US business increased 31% to ₹396 crore. For FY26, Torrent reported robust full-year numbers with net profit rising to ₹2,138 crore from ₹1,911 crore and revenue growing 21% to ₹13,980 crore from ₹11,516 crore in FY25. Analysts remain positive on the company’s strong domestic momentum and global portfolio expansion.